



SAPPHIRE PAVILION LIMITED

BIOTECH FUND

www.sapphire-pavilion.com

FUND DESCRIPTION

This Fund aims to gain the greatest possible return on investments by investing in global healthcare equities based on the rapid development in technology presents both challenges and opportunities to industry players, including pharmaceuticals, diagnostics, medical technology manufacturers, digital health vendors and healthcare service providers.

This Fund is suitable for investors seeking for potential long-term capital appreciation and potential growth by capturing value via investing in global healthcare business.

INVESTMENT OBJECTIVE

The Fund's are invested in equities issued by foreign and domestic issuers operating in or profiting from the healthcare industry. This includes companies involved in the biotech, pharmaceutical, medical, service and distribution of healthcare products.

WHY INVEST IN THE FUND

- Diversification across geographies, commodities, and operating models
- Robust due diligence and analysis of Environmental, Social, and Governance factors to help identify risk and hidden value
- Capitalize on economies of scale, productivity gains, and generate portfolio value impact
- Attractive profits yield from robust healthcare industry
- Optimize allocation of capital to different sectors and regions based on market conditions


FUND HIGHLIGHTS

| | |
|--|--|
| Fund Name | Biotech Fund |
| Type of Fund | Capital Growth and Regular Income Fund |
| Fund Size | Up to USD10.0 million |
| Lock in Period | 5 years with option to renew for subsequent 5 years |
| Initial Offer Price | USD 1.00 |
| Financial year end | 31st December |
| Share Type | Preference Shares with par value of USD 1.00 |
| Share Class | Single class |
| Investment Region | South East Asia |
| Investment Target | Healthcare |
| Coupon Rate | Up to 6.0% per annum |
| Amount | USD 300.0 million |
| Min. Subsequent Investment during the offer period | USD 5,000 or such other amounts as may be determined by the Manager from time to time. |
| Management fee | 2.0% |

VALUE CHAIN APPROACH



FUND PORTFOLIO ANALYSIS



Disclaimer

This piece is authorized for use by existing shareholders. A current Information Memorandum must accompany or precede this material if it is distributed to prospective investors. You should carefully consider the Fund's investment objective, risks, charges, and expenses before investing. Read the Information Memorandum carefully before you invest or send money. This does not constitute a recommendation of any investment strategy or product for a particular investor. Investors should consult a financial professional before making any investment decisions. This factsheet is prepared for information purposes only. It does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive it. Past performance is not necessarily a guide to future performance. Returns may vary from year to year. The Biotech Fund shall not be offered to Malaysian Resident in any part of Malaysia.

Objective and Risks. Biotech Fund investment objective is to provide capital growth and long-term income. There can be no assurance that the Fund will achieve its objective. Some important risks of an investment in the Fund are: **common stock risk:** an adverse event may have a negative impact on a company and could result in a decline in the price of its common stock; **fees and expenses risk:** the Fund may not earn enough through income and capital appreciation to offset the operating expenses of the Fund; **focused portfolio risk:** investing in a limited number of companies causes changes in the value of a single security to have a more significant effect on the value of the Fund's total portfolio; **headline risk:** the Fund may invest in a company when the company becomes the center of controversy. The company's stock may never recover or may become worthless; **large-capitalization companies risk:** companies with \$10 billion or more in market capitalization generally experience slower rates of growth in earnings per share than do mid- and small-capitalization companies; **manager risk:** poor security selection may cause the Fund to underperform relevant benchmarks; **mid- and small-capitalization companies risk:** companies with less than \$10 billion in market capitalization typically have more limited product lines, markets and financial resources than larger companies, and may trade less frequently and in more limited volume; **stock market risk:** stock markets have periods of rising prices and periods of falling prices, including sharp declines; and **variable current income risk:** the income which the Fund pays to investors is not stable. The value of investments and the income can fluctuate and is not guaranteed. Rates of exchange may cause the value of investments to go up or down. Investors may not get back the amount they invest.

Released on 28 July 2018

SAPPHIRE PAVILION LIMITED (Company No.: LL13761)

Unit Level 4(A), Main Office Tower, Financial Park Labuan, Jalan Merdeka, 87000 Federal Territory of Labuan, Malaysia. | Tel: +608-741 6111 | Email: info@sapphire-pavilion.com